Sarah Robertson

Dr. Sarah Robertson is a strategic cross-functional leader with over 15 years of experience in drug development and the commercialization of innovative therapeutics. They have held pivotal roles at prominent organizations such as the U.S. Food and Drug Administration, Vertex Pharmaceuticals, and argenx, overseeing critical projects in therapeutic areas including immunology and rare diseases. Notably, Dr. Robertson served as Project Lead for the first Triple Combination regimen for Cystic Fibrosis at Vertex and is currently enhancing asset strategy for efgartigimod at argenx. They have also contributed to the Clinical and Translational Science journal as an Associate Editor and are pursuing a Bachelor of Science in Chemistry at Marquette University.